Seattle Genetics shares are trading higher after RBC raised its price target from $89 to $90; noting that Merck pushing their estimated KEYNOTE-204 trial completion date from "any day now" to 2023 removes competitve overhang on Seattle's shares.
Benzinga Newsdesk